GlassScriptPhysician profile
Nimish Naik
NPI 1508910159
$109,365.95
in general payments reported to CMS, 2019-2025
20 companies · $51K in 2025
The $51K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,487 · 2021: $6,184 · 2022: $15K · 2023: $12K · 2024: $7,210 · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $14K · Food and Beverage: $5,825 · Consulting Fee: $4,300 · Education: $8.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,036.75 |
| Travel and Lodging | $14,415.58 |
| Food and Beverage | $5,825.39 |
| Consulting Fee | $4,300.00 |
| Education | $8.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $105,266.05 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $774.99 | 2020-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $736.60 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $552.13 | 2022-2025 | |
| Vifor Pharma, INC. | $448.18 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $354.79 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $315.80 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $174.03 | 2019-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $142.97 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $103.87 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.85 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $79.42 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $60.77 | 2021-2024 | Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $57.83 | 2024-2025 | |
| Novo Nordisk INC | $48.84 | 2025 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $48.06 | 2019 | |
| Lilly USA, LLC | $45.36 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $28.09 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $26.93 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $21.39 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimish Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.